Condition
Variegate Porphyria (VP)
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 54/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results67% success
Data Visualizations
Phase Distribution
1Total
P 3 (1)
Trial Status
Completed2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03338816Phase 3Completed
ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)
NCT01568554Completed
Clinical Diagnosis of Acute Porphyria
NCT03547297Terminated
INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients With Clinical Presentation and History Consistent With AHP
Showing all 3 trials